S
pinal muscular atrophy (SMA) is characterized by muscle weakness and severe physical disability attributed to motor neuron degeneration in the spinal cord and brainstem. It continues to represent the leading genetic cause of infant death attributed to respiratory insufficiency, with a pan-ethnic incidence of approximately 1 in 11,000 live births and a carrier frequency of 1 in 40 to 67. 1 The most common form of SMA is caused by mutations in the survival motor neuron 1 (SMN1) gene, resulting in SMN protein deficiency. 2 The almost identical survival motor neuron 2 (SMN2) gene produces a small amount of functional SMN protein, and SMN2 copy number is recognized as a major modulator of the SMA phenotype. 3 There have been significant advances in the understanding of the underlying pathogenic process in SMA. Concomitantly, there has been progress in defining disease progression and natural history, with a concerted effort in developing outcome measures and clinical trial readiness. Consequently, novel genetic therapies, aimed at modulating SMN protein expression, have resulted in significant clinical improvement in SMA patients for the first time, thereby providing much needed hope for the treatment of this devastating disease. As such, the present review will focus on recent advances made toward developing novel therapeutic strategies and future challenges as the field enters into a new treatment era.
Progress in Understanding the Natural History of SMA
SMA has a broad range of age of onset, severity, rate of progression, and variability between and within subtypes (Table 1) . 4, 5 In type I SMA, earlier age of onset is associated with worse prognosis and mortality 6 ; the median age to death or ventilation (>16 hours per day) is 13.5 months and 10.5 months for patients with 2 copies of SMN2. 5 Patients with SMA type II have a better prognosis than those with type I disease, with 93% surviving to 25 years. 6 After age 15, a relative stability in function develops with subsequent gradual decline over time. 7 Age of onset is also a predictor of functional ability, with patients classified as SMA IIIa having a 73% probability of walking 10 years after diagnosis, whereas SMA type IIIb patients have a 97% probability of walking 10 years after diagnosis. 8 A better understanding of the natural history of SMA has been crucial to the development of relevant outcome measures and implementation of clinical trials. Understanding variability in the rate of clinical progression in SMA related to age, SMA type, and ambulation status will assist in the development of appropriate motor function scales that are able to monitor subtle, but clinically meaningful changes (see Finkel et al 9 ) . The clinical heterogeneity in motor function is a challenge and connected with the range of possibilities for change in short time frames. The pattern of age-related changes in motor function in SMA types II and III is nonlinear, and there are different patterns of progression between ambulant and nonambulant patients. 7, 10 In nonambulant patients, variable improvement in motor function occurs up to 4 to 5 years of age, before functional ability (eg, in upper limbs) declines between 5 and 15 years. After age 15, a relative stability in function develops with subsequent gradual decline over time. 7 Decline in motor and respiratory function within a 12-month period was often minor, although progression was variable between individuals. 7, 9 This slow rate of progression, particularly in milder phenotypes, poses a major challenge to clinical trials in SMA because most trials need to be completed within 1 to 2 years. Rather than SMA phenotype, ambulant status may be more relevant to the trajectory of disease progression and consequently in trial design and outcome measure development. For instance, different outcome measures are required to monitor clinically important differences among ambulant and nonambulant cohorts, yet it will also be important to better connect scales that measure different functional levels to be able to more accurately demonstrate improvements. 10 In addition to motor function scales, neurophysiological studies have provided insights into clinical progression, timing of motor neuron loss, and compensation in SMA; however, these studies have predominantly focused on later stages of disease. Electrophysiological outcomes compound muscle action potential (CMAP) amplitude and motor unit number estimation (MUNE) correlate with age, SMA type, functional status, and 
Respiratory Management
Respiratory complications are the major cause of morbidity and mortality in SMA. The onset of peripheral hypoventilation may be asymptomatic and initially occur during sleep, but with deterioration daytime respiratory dysfunction develops. Objective measures of respiratory function are not routinely performed in children younger than 4 to 6 years because of complexity of the required maneuvers; potential alternative measures of respiratory function, for example, sniff nasal inspiratory pressure and forced oscillation techniques, have been proposed in this population because they are noninvasive and require less patient cooperation. 19 Attempts to identify nighttime hypoventilation using pulmonary testing in SMA patients have been largely unsuccessful, 20 highlighting the continued benefit of overnight polysomnography. Assessment frequency needs to be individualized, based on current functional status and rate of disease progression, and should be supplemented with other clinical observations, such as assessment for paradoxical breathing and chest wall growth, among others. The major respiratory complications faced by SMA patients include impaired cough-resulting in reduced clearance of lower airway secretions-hypoventilation, chest wall and lung underdevelopment, and recurrent infections that exacerbate muscle weakness. Although contentious, proactive management with noninvasive ventilation, even before the onset of paradoxical respirations, has led to improved survival, prevention, and improvement in chest wall deformity as well as improved quality of life. 21, 22 In addition, optimizing airway clearance is important for acute and chronic management of SMA patients with secretion mobilization techniques, such as assisted coughing, [23] [24] [25] physiotherapy, and postural drainage. 26 The decision to progress to invasive ventilation with tracheostomy remains an ethical dilemma, and considerable variability exists between countries with no consensus in guidelines. 17, 18 The goal of interventions should always be to improve quality of life with the provision of support and assistance to parents in making difficult decisions consonant with their values and beliefs.
Nutritional Support
Malnutrition is prevalent in SMA, with bulbar dysfunction and deterioration of nutritional status preceding and exacerbating respiratory failure with disease progression. 27, 28 Appropriate nutritional management of SMA patients is critical for improving quality of life and optimizing survival, 29 although no clear consensus exists on the timing of initiation of nutritional support.
Orthopedic Considerations
Scoliosis is a common complication of SMA, present in 60% to 95% of patients, secondary to progressive muscle weakness. In SMA types I and II, scoliosis occurs earlier and a more-severe, progressive curvature is evident compared to SMA type III. 30 Progression of scoliosis may exacerbate respiratory dysfunction, gastrointestinal reflux, and increase postural discomfort. 30 Management of scoliosis includes nonsurgical options, such as physical therapy, bracing, and seating modification, and depending on the strategy used, may slow, but not necessarily prevent, curve progression. Additionally, surgical approaches are utilized in progressive scoliosis, most frequently in type II and III SMA. Posterior spinal fusion is typically implemented after skeletal maturity during adolescence in SMA, with iliac fixation used to assist correction of pelvic obliquity. Innovative surgical techniques utilizing growing rods (eg, vertical prosthetic titanium rib or magnetic rods) enable spinal growth while avoiding repeated invasive surgeries; however, medium-to longer-term implications remain unclear. Although surgery does not reverse the respiratory reserve lost because of scoliosis, it leads to improved life quality 31 and can slow deterioration of respiratory function. 32 Finally, with an intrathecally administered therapy showing promise in phase 3 clinical trials, construction of bony windows may be considered to facilitate drug administration.
Genetic and Environmental Insights Into Pathogenesis
Whereas mutations in SMN1 characterize SMA, disease severity is also linked to a number of genetic modifiers. These modifiers are of relevance in enabling patient stratification in clinical trials, better prediction of an individual's prognosis, and establishing newborn screening.
Patients have variable copy numbers of the SMN2 gene, a related gene that differs from SMN1 by only five nucleotides, altering splicing and leading to transcription of a nonfunctional SMN protein lacking exon 7 in the majority of transcripts (Fig 1) . 33 SMN2 copy number is the main determinant of phenotype, although not solely sufficient to predict severity. 34 Sequence variations within the SMN2 gene and upregulation of modifier proteins, such as plastin 3, may also positively modify phenotype. [35] [36] [37] In addition, nutritional deficiency, oxidative stress, and hypoxia, partly attributed to gastrointestinal dysfunction, may cause widespread splicing alterations, including SMN2, and accelerate SMA progression.
38-40
How Low Levels of SMN Cause SMA Recent insights into the role of SMN within motor neurons have furthered our understanding of the implications of SMN deficiency. 41 The best characterized role of the SMN complex is in the assembly of Sm proteins (a distinctive family of RNA associated small proteins) onto small nuclear RNAs (snRNAs), forming small nuclear ribonucleoproteins (snRNPs), which are essential components of pre-mRNA splicing machinery in cells. 42 SMN deficiency and therefore reduced snRNP assembly capacity are proposed to cause aberrant splicing or transport of RNPs to the detriment of motor neurons. 43 A recent study showed transcriptional dysregulation in motor neurons isolated from very young presymptomatic SMA mice that preferentially affected a small subset of genes involved in synaptogenesis and maintenance of neuromuscular junctions (NMJs). 43 Furthermore, some of these dysregulated motor neuron relevant genes showed underlying splicing changes, strengthening a potential link between aberrant splicing and motor neuron vulnerability. 43 A second view of SMA pathogenesis contends that SMN has axonal function independent of splicing that may be disrupted in SMA. Consequently, SMN deficiency may impair targeting and local translation of axonal mRNAs essential for motor neuron development and maintenance. 44, 45 Furthermore, SMN regulates several other fundamental cellular processes in the neuronal cytoplasm that are critical for maintaining axonal and synaptic health, including endocytic pathways, local translation, mitochondrial transport, and targeting to axons and ubiquitin homeostasis. Animal Models of SMA Current understanding of SMA pathogenesis has been generated largely as a result of the availability of mouse models of SMA. These have been largely generated by targeting the endogenous mouse Smn gene, while using transgenic strategies to add variable copy numbers of the human SMN2 transgene. 52 These animal models tend to phenocopy severe forms of the human disease, resulting in the majority of animal-based work focusing on early postnatal phenotypes. Recently, alternative strategies have been used to generate mice modeling less-severe forms of SMA, allowing investigation of disease pathogenesis and preclinical drug testing more relevant to type II and III SMA. 53, 54 Additional animal models of SMA are also beginning to play an important role in SMA research, including Drosophila and zebrafish, 55, 56 and recent developments suggesting that large animal models (eg, pigs) may be forthcoming. 57 Although alpha motor neurons in the spinal cord remain the primary pathological target in SMA, 58 there is now accumulating evidence suggesting that other cells, tissues, and organs contribute to disease symptoms (Fig 2) . 59, 60 For example, there is now experimental evidence suggesting a non-cell-autonomous contribution to motor neuron degeneration from astrocytes and Schwann cells. 61, 62 Likewise, low levels of SMN in skeletal muscle have been implicated in SMA pathogenesis with significant disruption of the molecular composition of skeletal muscle evident in presymptomatic severe SMA mice in the absence of detectable changes in lower motor neurons. 63 One potential unifying factor may be a deficiency in the development of vasculature in SMA; the resulting hypoxia would likely impact motor neurons as well as skeletal muscle and possibly contribute to the gastrointestinal defects (gastroesophageal reflux, constipation, and delayed gastric emptying) commonly observed in SMA patients. 64 Although the mechanisms mediating the effects of vascular depletion have not been fully elucidated, hypoxia has been identified as a modifier of SMN2 splicing, potentially explaining some of the splicing alterations observed in SMA. 38, 39, 65 Disease-associated phenotypes have been reported across a range of other organs in SMA mice (in some cases supported by data from human patients). These include functional and structural cardiac defects, 66 abnormal development of the gastrointestinal tract, liver, and spleen, 64, 67, 68 and irregular bone remodeling and skeletal pathology. 69 These findings suggest that successful treatment of SMA may require systemic targeting of a range of affected tissues. However, how these findings will translate to humans is uncertain, for example, heart defects are rare in humans.
Defining the Therapeutic Window in Animal Models
In severe SMA mice, induction of SMN expression at gestation or in the early postnatal period substantially improves survival, whereas later induction is less effective. 70, 71 Mice are resistant to SMN depletion after early postnatal stages, suggesting that there is a period of sensitivity to low SMN levels and that high SMN levels are required during this early postnatal stage. 70, 72 Notably, in mouse models, the time period when SMN function is required coincides with the neonatal period of NMJ establishment, development, and maturation, suggesting that the mechanistic underpinnings of the therapeutic window are based on the pathways driving normal NMJ maturation. These observations imply that early correction of SMN levels in SMA types II and III is likely to be necessary and sufficient to protect the neuromuscular system, and lifelong expression of SMN may not be required.
Whereas most preclinical studies investigating SMN restoration in animals were limited to evaluating presymptomatic administration of gene therapy with viral vectors or antisense oligonucleotides to correct SMN2 splicing and enhance SMN expression, which, in most cases, robustly improves the health of SMA mice, some studies have tested the impact of pre-and postsymptomatic SMN restoration. Systemic delivery of these approaches largely rescued SMA mice's motor function, neuromuscular physiology, and life span when delivered within the first 3 postnatal days (P0-P3), but were less effective beyond P5 and gene therapy was not effective at P10, confirming the presence of a narrow therapeutic window. 73, 74 However, SMN restoration using intravenous injection of self-complementary adeno-associated virus (scAAV9)-SMN vectors given at symptom onset had a marked effect with amelioration of severe proximal weakness and electrophysiological indices, in a porcine model of SMA 57 which may represent a more-relevant model for predicting efficacy in humans. Even so, presymptomatic delivery prevented the development of symptoms, suggesting that therapeutic windows are still critical in this model. Whereas it is accepted that animal models cannot recapitulate human SMA precisely, the translation of concepts of motor neuron degeneration to humans suggests that presymptomatic or earlysymptomatic restoration of SMN (during NMJ maturation) will likely produce the best response to therapy. An unresolved issue remains as to whether commencing therapy in older patients will be effective. The time course and extent of motor neuron loss in type III or IV has never properly been mapped, largely attributed to a paucity of robust animal models of less-severe forms of SMA. Encouragingly, recent results from models of milder SMA phenotypes suggest that some therapeutic efficacy may be possible even at late disease stages. 75 Although the therapeutic window for SMA types III and IV has not been defined, the normal early motor development may suggest that it is linked to age of presentation and broader than types I and II. Preliminary clinical trial data are emerging and indicating that with SMN repletion motor neurons may not be irreversibly doomed. However, animal models recapitulating severe SMA show rapid postnatal motor neuron attrition and reduced efficacy with delayed treatments, such that the optimal success may ultimately arise from presymptomatic provision of therapy.
73,76
Therapeutic Developments
The pipeline of therapies for SMA encompasses four different strategies, including SMN1 gene replacement, modulation of SMN2 encoded full-length protein levels, neuroprotection, and targeted improvements of muscle strength and function (Fig 3) . Translational research continues to progress and clinical trials have recently reporting positive preliminary results related to safety and efficacy of the newest approaches (Table 3 ). This follows a number of negative clinical trials of repurposed drugs, including valproic acid and acetyl-L-carnitine, phenylbutyrate hydroxyurea, riluzole, and somatotropin, [77] [78] [79] despite promising preclinical data. Importantly, these negative studies have informed clinical trial design, validated the reliability and feasibility of specific outcome measures, and highlighted the importance of patient stratification. In a mouse model of severe SMA, postnatal intravenous gene therapy using a viral vector rescued motor function and neurophysiology and extended survival from 2 weeks to beyond 250 days. 70 The most advanced compound known to increase production of fully functional SMN protein is nusinersen (IONIS-SMN RX ), an antisense oligonucleotide administered intrathecally that modifies the splicing of SMN2. A phase 1 open label study of nusinersen in 28 SMA II and III patients aged 2 to 14 years reported that the drug was well tolerated with no safety concerns identified. 82 Transient back pain and postlumbar puncture headache were of a similar frequency to previous reports in infants and children undergoing lumbar puncture. Favorable time-and dose-dependent increases in muscle FIGURE 3: Therapeutic targets for SMA being investigated in clinical trials. SMN1 gene replacement therapy utilizes a selfcomplementary adeno-associated viral vector (AAV9-SMN) that crosses the blood-brain barrier following intravenous administration. Compounds that increase the production of fully functional SMN protein by modifying the splicing of SMN2 include the orally available small molecules, RG7916 and LMI070, and the intrathecally administered antisense oligonucleotide, nusinersen, which acts by displacing heterogenous nuclear ribonucleoprotein (hnRP) proteins from the intronic splicing silencer site on the SMN2 pre-mRNA. The neuroprotective effects of olesoxime, through altered mitochondrial permeability, and exercise, through greater motor neuron survival, maintenance of neuromuscular junctions, and improved neuromuscular excitability properties, are being investigated. Additional strategies focused on improving neuromuscular function and physical performance include CK-2127107, a fast skeletal troponin activator that sensitizes the sarcomere to calcium and increases the contractile response to nerve signaling, and 4-aminopyridine and pyridostigmine that may facilitate neurotransmitter release and increase its synaptic duration. mRNA 5 messenger RNA; SMN 5 survival motor neuron. [Color figure can be viewed at wileyonlinelibrary.com] Orally bioavailable small molecules are being developed for selective SMN2 splicing correction, and several (RG 7916 and LM1070) are entering early phase clinical trials. Administration of these compounds to mice with severe SMA increased SMN protein levels, motor function, and survival (from 18 to beyond 150 days). 76, 86 Further clinical trials are also needed to define the efficacy of salbutamol, a b agonist that promotes exon 7 inclusion in SMN2 transcripts, following encouraging early results from several pilot studies in SMA patients. 87 Increasing the expression of SMN2 with small molecules, such as quinazoline-derived compounds, moderately increased SMN mRNA and protein levels as well as survival in severe SMA mice. 88 However, plans to progress beyond phase 1 clinical trials have been terminated, reflecting challenges in translating disease-modifying benefits from mouse to human. Olesoxime has entered clinical trials in SMA patients following demonstration of its neuroprotective properties motor neurons in cell culture and SMA mice. Phase 2 trials have been completed and though the primary endpoint was not statistically significant, a greater percentage of patients were stable or improved compared to placebo, suggesting that olesoxime may slow decline in motor function over 2 years in already symptomatic patients with SMA types II and III. 89 However, further data are needed to determine whether this is a clinically meaningful effect. Additional strategies focused on improving neuromuscular function and physical performances in SMA patients are also being assessed in clinical trials. Among these is CK-2127107, which slows calcium release from fast skeletal muscle troponin and sensitizes the sarcomere to calcium thus increasing contractile response to nerve signalling; studies have demonstrated its efficacy in mouse models of motor neuron disease and it appears safe in healthy human volunteers. 90 Additionally, exercise-induced neuroprotection has recently been demonstrated in SMA-like mice with greater motor neuron survival, maintenance of neuromuscular junctions, and improved neuromuscular excitability properties, accompanied by positive metabolic and behavioral changes. 91 The benefits and risks of different types of exercise are being evaluated in SMA patients, and initial studies have demonstrated that resistance training is feasible, safe, and well tolerated and aerobic training increases oxidative capacity. 92 
Conclusions and Future Directions
There have been tremendous advances in therapeutic development in SMA, with treatment options rapidly evolving and preliminary results of clinical trials in patients producing new hope. In parallel, there has been substantial progress in understanding clinical disease progression and natural history to accelerate the implementation of clinical trials. Rodent models suggest that requirements for normal SMN levels are paramount during development of the motor unit, with SMN restoring therapies most effective early. The translation of these concepts to humans is needed to determine whether therapy in later stages of disease is beneficial. Critical for timely access to novel disease-modifying treatments is the rapid recognition of clinical manifestations and diagnosis, with presymptomatic diagnosis to guard against disease onset and progression the ultimate aim. Population-based newborn screening pilot programs are determining the feasibility and reliability of presymptomatic diagnosis, and effective molecular methods have been validated on dried blood spots, including real-time polymerase chain reaction and high-resolution melting analysis. [100] [101] [102] [103] Improvements in multidisciplinary clinical care, together with advances in technology, have changed the natural history for patients with SMA. With new therapeutics emerging, it is likely that profound shifts in management approaches will transpire in severe SMA. These will also necessitate additional validation of nonmotor standardized and reliable outcome measures, particularly respiratory assessments, given that these are functionally meaningful and contribute substantially to morbidity. Secondary complications, such as scoliosis and contractures, may further limit the value of existing motor outcome measures. Furthermore, individual motor function scales are relevant to specific levels of SMA severity, and it will be important to better connect scales that measure different functional levels to be able to more accurately demonstrate improvements. Whereas motor function scales are a major focus and most relevant to SMA, strength testing, electrophysiological assessments, and metabolomic and proteomic outcomes measures are also being integrated into natural history studies and clinical trials in SMA. 104 With the tantalizing prospect of novel therapies moving closer to clinical reality, more questions arise, compelling the formation of collaborative and linked future monitoring programs to determine the impact of these therapies. Longer-term monitoring programs should also include assessments of cognition, growth, autonomic function, and adverse events and enable a comparison and evaluation of combined treatments. These will serve to understand how novel therapies may affect phenotype over the longer term and the duration of effect-will they reduce progression, as well as stabilize or improve function? How will they affect requirements for permanent ventilation or age of death? What is the potential variability of responsiveness of different motor neuron subpopulations attributed to drug distribution or inherent differences in reversibility? Furthermore, the possibility that reinnervation may stress remaining motor neurons, resulting in a post-polio-like condition with late deterioration, must be considered. It is likely that combined therapies increasing SMN levels while also enhancing and preserving neuromuscular function and preventing additional systemic pathology will provide the best approach. In the setting of a first-in-class approved therapy, continued progress in developing secondgeneration and combination therapies will require innovative approaches in trial design. In addition, new challenges are arising with emerging therapies, including difficulties with access to treatment associated with the complexities, costs, and expertise required with intrathecal administration. Further efforts to ascertain optimal routes of drug delivery and distribution and defining the therapeutic window will be essential.
As the field looks toward a new treatment era, it is necessary to focus on timely access to novel, diseasemodifying therapy and endeavoring to develop therapies for patients with SMA of all ages and severities.
